Data Integrity Remains Challenging For API Manufacturers
FDA Office Of Compliance Data Highlights Deficiencies
Executive Summary
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.
You may also be interested in...
First-Ever OTC Inspections Drove Surge Of FDA Warning Letters In FY 2019
The good news: 75% of never-before-inspected firms complied with US drug GMP requirements. The bad news: 25% did not.
US FDA Pressing Repackers To Disclose API Suppliers In Case Quality Issues Arise
The FDA's Francis Godwin tells Pink Sheet of progress battling supply chain obfuscation, which could allow marketing of adulterated drugs; Yino warning letter is latest salvo.
US FDA Warning Letter Draws Indian Solvent Recycler Into Valsartan Crisis
Lantech’s solvent recovery operations expected to meet US drug GMP requirements due to risk of carcinogens in blood pressure medications.